Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 476, Issue -, Pages 79-83Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2018.04.011
Keywords
Follicle stimulating hormone; FSH receptor; Angiogenesis; Placenta
Categories
Funding
- National Institutes of Health [T32DK007690]
- Office of the Vice President for Research and Economic Development
- Holden Comprehensive Cancer Center
- Carver College of Medicine
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007690] Funding Source: NIH RePORTER
Ask authors/readers for more resources
It has been shown in both human and mouse placentas that follicle stimulating hormone receptor (FSHR) is expressed in fetal vascular endothelium. There are conflicting reports, however, on the role of FSH to stimulate angiogenesis in vitro in cultured endothelial cells from umbilical veins. Therefore, in this study we undertook an in vivo approach utilizing Fshr null mice to definitively address this question. In the context where all pregnant dams have identical Fshr genotypes, we generated fetuses and associated fetal portions of placenta that were Fshr wt or Fshr null and analyzed angiogenesis within the placental labyrinths. Quantitative morphometric analyses of placentas obtained at mid-gestation revealed that the percentage of the placenta composed of labyrinth is significantly decreased in Fshr null placentas relative to wt placentas. Furthermore, data presented demonstrate that within the Fshr null labyrinths, fetal vessel angiogenesis was significantly reduced relative to wt labyrinths. The results obtained with this combination of in vivo and genetic approaches conclusively demonstrate that signaling through endothelial FSHR does indeed stimulate angiogenesis and that placental Fshr is essential for normal angiogenesis of the fetal placental vasculature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available